Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04176380 · ClinicalTrials.gov registry record · Phase 2
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
A Phase 2 study, sponsored by Rapa Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04176380 is a Phase 2 study that has completed, run by Rapa Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT04176380, a Phase 2 study, has completed, sponsored by Rapa Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
Interventions
- BIOLOGICAL RAPA-201 Autologous T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2023-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04176380
The ClinicalTrials.gov registry entry for NCT04176380 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rapa Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAPA-201 Autologous T cells is the first listed.
NCT04176380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04176380 about?
NCT04176380 is a clinical study titled "RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma". RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
What is the current status of trial NCT04176380?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-12-02. Estimated completion is 2023-06-06.
What interventions are being tested in trial NCT04176380?
The interventions under investigation include: RAPA-201 Autologous T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04176380?
This trial is sponsored by Rapa Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.